WINT.OOTC
- Windtree Therapeutics, Inc.
报价延迟最少15分钟:2026/01/18 06:12 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.0201 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
323.08/-2.16
|
|
企业价值
1.33M
|
| 资产负债 |
|
每股账面净值
-0.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||
|
||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |
